Published in J Clin Invest on July 02, 2012
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 1.08
"Snorkeling" for missing players in cancer. J Clin Invest (2012) 1.05
The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J (2012) 1.00
The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev (2014) 0.89
The emerging landscape of small nucleolar RNAs in cell biology. Wiley Interdiscip Rev RNA (2015) 0.89
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med Genomics (2013) 0.87
Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut (2015) 0.86
Regulatory role of small nucleolar RNAs in human diseases. Biomed Res Int (2015) 0.85
MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J (2013) 0.85
The increased expression of 14q32 small nucleolar RNA transcripts in promyelocytic leukemia cells is not dependent on PML-RARA fusion gene. Blood Cancer J (2012) 0.81
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget (2016) 0.81
Overexpression of SNORD114-3 marks acute promyelocytic leukemia. Leukemia (2013) 0.79
Profiling of Small Nucleolar RNAs by Next Generation Sequencing: Potential New Players for Breast Cancer Prognosis. PLoS One (2016) 0.78
Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res (2016) 0.77
Lamina Associated Polypeptide 1 (LAP1) Interactome and Its Functional Features. Membranes (Basel) (2016) 0.77
A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. PLoS One (2014) 0.77
A Fleeting Glimpse Inside microRNA, Epigenetics, and Micropeptidomics. Adv Exp Med Biol (2015) 0.76
Rpl13a small nucleolar RNAs regulate systemic glucose metabolism. J Clin Invest (2016) 0.75
Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. FASEB J (2016) 0.75
Urb-RIP - An Adaptable and Efficient Approach for Immunoprecipitation of RNAs and Associated RNAs/Proteins. PLoS One (2016) 0.75
Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget (2017) 0.75
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Mol Oncol (2015) 0.75
Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res (1981) 61.59
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Multiple myeloma. N Engl J Med (2011) 10.38
Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods (2002) 3.73
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood (1998) 3.69
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 3.11
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol (2007) 2.85
A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature (2009) 2.74
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (1997) 2.31
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res (2007) 2.19
Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab (2011) 2.16
Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol (2008) 1.96
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol (2008) 1.93
Human box H/ACA pseudouridylation guide RNA machinery. Mol Cell Biol (2004) 1.85
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Biogenesis and intranuclear trafficking of human box C/D and H/ACA RNPs. Cold Spring Harb Symp Quant Biol (2006) 1.80
Box H/ACA small ribonucleoproteins. Mol Cell (2010) 1.79
Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol (2006) 1.72
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
Mammalian small nucleolar RNAs are mobile genetic elements. PLoS Genet (2006) 1.55
Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma (2011) 1.52
t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. Br J Haematol (2003) 1.49
Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol (2006) 1.33
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res (2011) 1.26
Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage. Proc Natl Acad Sci U S A (2011) 1.18
A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol (2001) 1.17
MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun (2008) 1.09
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res (2004) 0.97
MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res (2011) 0.93
Proteomic analysis of anoxia tolerance in the developing zebrafish embryo. Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.89
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell (2013) 6.30
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood (2012) 2.77
Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 2.14
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood (2010) 2.01
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood (2005) 1.96
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant (2008) 1.77
ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol (2004) 1.77
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica (2013) 1.76
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol (2006) 1.72
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2004) 1.70
An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2003) 1.69
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A (2003) 1.69
Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest (2011) 1.66
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol (2011) 1.66
FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One (2013) 1.65
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol (2009) 1.63
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood (2007) 1.55
Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol (2012) 1.53
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell (2010) 1.48
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer (2013) 1.48
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest (2008) 1.41
Proteasome activator PA200 is required for normal spermatogenesis. Mol Cell Biol (2006) 1.38
Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol (2006) 1.33
Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation (2003) 1.32
Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci U S A (2010) 1.25
β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol (2013) 1.22
Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood (2007) 1.19
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest (2010) 1.18
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood (2008) 1.16
CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity. Circ Res (2010) 1.15
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 1.15
Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol (2011) 1.14
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood (2011) 1.13
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol (2014) 1.13
ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood (2013) 1.09
Effect of focal adhesion proteins on endothelial cell adhesion, motility and orientation response to cyclic strain. Ann Biomed Eng (2009) 1.08
Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood (2011) 1.08
TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res (2007) 1.08
Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood (2008) 1.06
Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol (2013) 1.06
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood (2012) 1.04
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest (2013) 1.04
Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer (2009) 1.03
Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem (2007) 1.03
Transfusion medicine illustrated. Unnecessary transfusions due to pseudothrombocytopenia. Transfusion (2004) 1.02
A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol Cell Biol (2007) 1.00
Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages. J Immunol (2006) 0.99
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res (2013) 0.98
Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection. J Immunol (2003) 0.96
Intramyocellular lipid content and insulin sensitivity are increased following a short-term low-glycemic index diet and exercise intervention. Am J Physiol Endocrinol Metab (2011) 0.96
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget (2012) 0.94
Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. Cancer Epidemiol Biomarkers Prev (2008) 0.94
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood (2013) 0.94
Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget (2013) 0.94
Preclinical MR fingerprinting (MRF) at 7 T: effective quantitative imaging for rodent disease models. NMR Biomed (2015) 0.93
Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Exp Hematol (2009) 0.93
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol (2012) 0.93
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol (2009) 0.93
[Analysis of mutation of BIGH3 gene in Chinese patients with corneal dystrophies]. Zhonghua Yan Ke Za Zhi (2003) 0.92
Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Singapore Med J (2012) 0.92
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One (2013) 0.91
Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma (2007) 0.90
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma. PLoS One (2013) 0.90
Influence of body mass index on survival in veterans with multiple myeloma. Oncologist (2013) 0.90
Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2013) 0.89
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs (2013) 0.88